CD274 and malignant colon neoplasm: Though approved by Food and Drug Administration (FDA) for the blockade of PD‐L1 to advance immune response, the clinical application of the anti‐PD‐L1 antibody is impeded by the high cost and inferior pharmacokinetics (e.g., clearance by the innate immune system).[24] Therefore, a platform, which can improve in vivo pharmacokinetics of economical alternatives for immune checkpoint PD‐L1 blockade and CpG, appears to be the best scenario to empower photodynamic immunotherapy of colon cancer.